{"abstract":"The National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the National Center for Advancing Translational Sciences (NCATS), both institutes of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), are contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Autala Bio Inc., A Civala Company (\"Autala\"), incorporated in Delaware.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2024/08/16/2024-18381.html","cfr_references":[],"citation":"89 FR 66730","comment_url":null,"comments_close_on":"2024-09-03","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license that are received by the National Heart Lung and Blood Institute (NHLBI) Office of Technology Transfer And Development (OTTAD) on or before September 3, 2024 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2024-18381","effective_on":null,"end_page":66731,"executive_order_notes":null,"executive_order_number":null,"explanation":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2024/08/16/2024-18381.xml","html_url":"https://www.federalregister.gov/documents/2024/08/16/2024-18381/prospective-grant-of-an-exclusive-patent-license-dimethyl-synaptamide-for-the-treatment-of","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2024-18381?publication_date=2024-08-16","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2024-08-16/2024-18381/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":86,"last_updated":"2026-04-04 16:15:04 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-08-16/pdf/2024-18381.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-18381.pdf?1723725945","publication_date":"2024-08-16","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2024/08/16/2024-18381.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2024-08-16T08:50:06Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":66730,"subtype":null,"title":"Prospective Grant of an Exclusive Patent License: Dimethyl Synaptamide for the Treatment of Autoimmune Disorders and Inflammatory Diseases","toc_doc":"Dimethyl Synaptamide for the Treatment of Autoimmune Disorders and Inflammatory Diseases","toc_subject":"Licenses; Exemptions, Applications, Amendments, etc.:\n","topics":[],"type":"Notice","volume":89}